Literature DB >> 17936562

Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer.

Ali Mallakin1, Takayuki Sugiyama, Pankaj Taneja, Lauren A Matise, Donna P Frazier, Mayur Choudhary, Gregory A Hawkins, Ralph B D'Agostino, Mark C Willingham, Kazushi Inoue.   

Abstract

Dmp1 (Dmtf1) is activated by oncogenic Ras-Raf signaling and induces cell-cycle arrest in an Arf, p53-dependent fashion. The survival of K-ras(LA) mice was shortened by approximately 15 weeks in both Dmp1(+/-) and Dmp1(-/-) backgrounds, the lung tumors of which showed significantly decreased frequency of p53 mutations compared to Dmp1(+/+). Approximately 40% of K-ras(LA) lung tumors from Dmp1(+/+) mice lost one allele of the Dmp1 gene, suggesting the primary involvement of Dmp1 in K-ras-induced tumorigenesis. Loss of heterozygosity (LOH) of the hDMP1 gene was detectable in approximately 35% of human lung carcinomas, which was found in mutually exclusive fashion with LOH of INK4a/ARF or that of P53. Thus, DMP1 is a pivotal tumor suppressor for both human and murine lung cancers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17936562      PMCID: PMC2239345          DOI: 10.1016/j.ccr.2007.08.034

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  51 in total

Review 1.  Haplo-insufficiency? Let me count the ways.

Authors:  K C Quon; A Berns
Journal:  Genes Dev       Date:  2001-11-15       Impact factor: 11.361

Review 2.  Gene silencing in cancer in association with promoter hypermethylation.

Authors:  James G Herman; Stephen B Baylin
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245

Review 3.  Pathology of lung cancer.

Authors:  William D Travis
Journal:  Clin Chest Med       Date:  2002-03       Impact factor: 2.878

4.  Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas.

Authors:  K Inoue; F Zindy; D H Randle; J E Rehg; C J Sherr
Journal:  Genes Dev       Date:  2001-11-15       Impact factor: 11.361

Review 5.  Molecular pathogenesis of lung cancer.

Authors:  Sabine Zochbauer-Muller; Adi F Gazdar; John D Minna
Journal:  Annu Rev Physiol       Date:  2002       Impact factor: 19.318

6.  ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells.

Authors:  Rebecca S Muraoka; Anne E G Lenferink; Brian Law; Elizabeth Hamilton; Dana M Brantley; L Renee Roebuck; Carlos L Arteaga
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

Review 7.  The TP53 gene, tobacco exposure, and lung cancer.

Authors:  Shinichi Toyooka; Toshihide Tsuda; Adi F Gazdar
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

Review 8.  Lung cancer. 9: Molecular biology of lung cancer: clinical implications.

Authors:  K M Fong; Y Sekido; A F Gazdar; J D Minna
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

Review 9.  Tumor suppression by Ink4a-Arf: progress and puzzles.

Authors:  Scott W Lowe; Charles J Sherr
Journal:  Curr Opin Genet Dev       Date:  2003-02       Impact factor: 5.578

10.  Alternative splicing of the human cyclin D-binding Myb-like protein (hDMP1) yields a truncated protein isoform that alters macrophage differentiation patterns.

Authors:  Mario P Tschan; Kimberlee M Fischer; Vivian S Fung; Farzaneh Pirnia; Markus M Borner; Martin F Fey; Andreas Tobler; Bruce E Torbett
Journal:  J Biol Chem       Date:  2003-08-12       Impact factor: 5.157

View more
  47 in total

1.  Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Invest       Date:  2018-11-05       Impact factor: 2.176

2.  Stabilization of the p53-DNA Complex by the Nuclear Protein Dmp1α.

Authors:  Robert D Kendig; Fumitake Kai; Elizabeth A Fry; Kazushi Inoue
Journal:  Cancer Invest       Date:  2017-04-13       Impact factor: 2.176

3.  Aberrant expression of p16INK4a in human cancers - a new biomarker?

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Rep Rev       Date:  2018-01-15

Review 4.  Role of DMP1 and its future in lung cancer diagnostics.

Authors:  Takayuki Sugiyama; Donna P Frazier; Pankaj Taneja; Rachel L Morgan; Mark C Willingham; Kazushi Inoue
Journal:  Expert Rev Mol Diagn       Date:  2008-07       Impact factor: 5.225

5.  Aberrant Expression of p14ARF in Human Cancers: A New Biomarker?

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Tumor Microenviron       Date:  2019-02-04

6.  Aberrant expression of cyclin D1 in cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Sign Transduct Insights       Date:  2015-09-20

7.  Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis.

Authors:  Paola Dongiovanni; Anna Ludovica Fracanzani; Gaetano Cairo; Chiara Paola Megazzini; Stefano Gatti; Raffaela Rametta; Silvia Fargion; Luca Valenti
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

8.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue
Journal:  Clin Med Insights Oncol       Date:  2010-04-20

9.  Bmi1 is critical for lung tumorigenesis and bronchioalveolar stem cell expansion.

Authors:  Jennifer Shepard Dovey; Sima J Zacharek; Carla F Kim; Jacqueline A Lees
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-12       Impact factor: 11.205

10.  Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer.

Authors:  D Maglic; S Zhu; E A Fry; P Taneja; F Kai; R D Kendig; T Sugiyama; L D Miller; M C Willingham; K Inoue
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.